301 related articles for article (PubMed ID: 34366231)
1. Risk factors for acute kidney injury in vancomycin and piperacillin/tazobactam combination therapy: A retrospective study.
Yamashita Y; Kawaguchi H; Yano T; Sakurai N; Shibata W; Oshima K; Imai T; Yamada K; Nakamura Y; Nagayama K; Kakeya H
J Infect Chemother; 2021 Nov; 27(11):1614-1620. PubMed ID: 34366231
[TBL] [Abstract][Full Text] [Related]
2. Incidence of acute kidney injury after teicoplanin- or vancomycin- and piperacillin/tazobactam combination therapy: A comparative study using propensity score matching analysis.
Sazanami K; Inose R; Yagi T; Dote S; Horiuchi N; Kobayashi Y; Muraki Y
J Infect Chemother; 2021 Dec; 27(12):1723-1728. PubMed ID: 34446352
[TBL] [Abstract][Full Text] [Related]
3. Risk of Acute Kidney Injury in Patients on Concomitant Vancomycin and Piperacillin-Tazobactam Compared to Those on Vancomycin and Cefepime.
Navalkele B; Pogue JM; Karino S; Nishan B; Salim M; Solanki S; Pervaiz A; Tashtoush N; Shaikh H; Koppula S; Koons J; Hussain T; Perry W; Evans R; Martin ET; Mynatt RP; Murray KP; Rybak MJ; Kaye KS
Clin Infect Dis; 2017 Jan; 64(2):116-123. PubMed ID: 27986669
[TBL] [Abstract][Full Text] [Related]
4. Incidence and Risk Factors of Acute Kidney Injury in Patients Receiving Concomitant Vancomycin and Continuous-Infusion Piperacillin/Tazobactam: A Retrospective Cohort Study.
Blair K; Covington EW
Ann Pharmacother; 2020 Nov; 54(11):1096-1101. PubMed ID: 32406243
[TBL] [Abstract][Full Text] [Related]
5. Lowered Risk of Nephrotoxicity through Intervention against the Combined Use of Vancomycin and Tazobactam/Piperacillin: A Retrospective Cohort Study.
Oda K; Hashiguchi Y; Katanoda T; Nakata H; Jono H; Saito H
Microbiol Spectr; 2021 Sep; 9(1):e0035521. PubMed ID: 34346742
[TBL] [Abstract][Full Text] [Related]
6. Association of Acute Kidney Injury With Concomitant Vancomycin and Piperacillin/Tazobactam Treatment Among Hospitalized Children.
Downes KJ; Cowden C; Laskin BL; Huang YS; Gong W; Bryan M; Fisher BT; Goldstein SL; Zaoutis TE
JAMA Pediatr; 2017 Dec; 171(12):e173219. PubMed ID: 28973124
[TBL] [Abstract][Full Text] [Related]
7. Epidemiology of Acute Kidney Injury among Patients Receiving Concomitant Vancomycin and Piperacillin-Tazobactam: Opportunities for Antimicrobial Stewardship.
Karino S; Kaye KS; Navalkele B; Nishan B; Salim M; Solanki S; Pervaiz A; Tashtoush N; Shaikh H; Koppula S; Martin ET; Mynatt RP; Murray KP; Rybak MJ; Pogue JM
Antimicrob Agents Chemother; 2016 Jun; 60(6):3743-50. PubMed ID: 27067325
[TBL] [Abstract][Full Text] [Related]
8. Retrospective Cohort Study of the Incidence of Acute Kidney Injury with Vancomycin Area under the Curve-Based Dosing with Concomitant Piperacillin-Tazobactam Compared to Meropenem or Cefepime.
Kiley PS; Pearston AP; Hodge LA; Kaplan MC; Baczek SM; Stanley JS; Wilson TJ; Soriano KM; Yao A; Shaeffer ZA; Talt IE; Cohen JA; Ingemi AI
Antimicrob Agents Chemother; 2022 Aug; 66(8):e0004022. PubMed ID: 35867523
[TBL] [Abstract][Full Text] [Related]
9. Short Versus Extended Duration Vancomycin and Piperacillin/Tazobactam and the Incidence of Acute Kidney Injury in Noncritically Ill Patients.
Traversa A; Hammond DA; Peksa GD; DeMott JM
J Pharm Pract; 2021 Dec; 34(6):882-887. PubMed ID: 32578474
[TBL] [Abstract][Full Text] [Related]
10. Comparative Incidence of Acute Kidney Injury in Critically Ill Patients Receiving Vancomycin with Concomitant Piperacillin-Tazobactam or Cefepime: A Retrospective Cohort Study.
Hammond DA; Smith MN; Painter JT; Meena NK; Lusardi K
Pharmacotherapy; 2016 May; 36(5):463-71. PubMed ID: 26952639
[TBL] [Abstract][Full Text] [Related]
11. Vancomycin with concomitant piperacillin/tazobactam vs. cefepime or meropenem associated acute kidney injury in the critically ill: A multicenter propensity score-matched study.
Buckley MS; Komerdelj IA; D'Alessio PA; Rangan P; Agarwal SK; Tinta NC; Martinez BK; Ziadat DS; Yerondopoulos MJ; Kobic E; Kane-Gill SL
J Crit Care; 2022 Feb; 67():134-140. PubMed ID: 34768175
[TBL] [Abstract][Full Text] [Related]
12. Acute kidney injury risk associated with piperacillin/tazobactam compared with cefepime during vancomycin therapy in hospitalised patients: a cohort study stratified by baseline kidney function.
Jeon N; Staley B; Klinker KP; Hincapie Castillo J; Winterstein AG
Int J Antimicrob Agents; 2017 Jul; 50(1):63-67. PubMed ID: 28522340
[TBL] [Abstract][Full Text] [Related]
13. Effect of concomitant vancomycin and piperacillin-tazobactam on frequency of acute kidney injury in pediatric patients.
Buhlinger KM; Fuller KA; Faircloth CB; Wallace JR
Am J Health Syst Pharm; 2019 Aug; 76(16):1204-1210. PubMed ID: 31369115
[TBL] [Abstract][Full Text] [Related]
14. The concomitant use of vancomycin and piperacillin-tazobactam is associated with acute kidney injury (AKI) in extremely low birth weight infants (ELBW).
Al-Jebawi Y; Karalic K; Shekhawat P; Mhanna MJ
J Neonatal Perinatal Med; 2022; 15(2):303-309. PubMed ID: 34864693
[TBL] [Abstract][Full Text] [Related]
15. Effect of serum concentration and concomitant drugs on vancomycin-induced acute kidney injury in haematologic patients: a single-centre retrospective study.
Okada N; Chuma M; Azuma M; Nakamura S; Miki H; Hamano H; Goda M; Takechi K; Zamami Y; Abe M; Ishizawa K
Eur J Clin Pharmacol; 2019 Dec; 75(12):1695-1704. PubMed ID: 31511938
[TBL] [Abstract][Full Text] [Related]
16. Incidence of Acute Kidney Injury Among Patients Receiving the Combination of Vancomycin with Piperacillin-Tazobactam or Meropenem.
Robertson AD; Li C; Hammond DA; Dickey TA
Pharmacotherapy; 2018 Dec; 38(12):1184-1193. PubMed ID: 30175410
[TBL] [Abstract][Full Text] [Related]
17. Acute kidney injury with combination vancomycin and piperacillin-tazobactam therapy in the ICU: A retrospective cohort study.
O'Callaghan K; Hay K; Lavana J; McNamara JF
Int J Antimicrob Agents; 2020 Jul; 56(1):106010. PubMed ID: 32413387
[TBL] [Abstract][Full Text] [Related]
18. [Risk of Acute Kidney Injury in Patients Treated with Vancomycin and Piperacillin/Tazobactam Compared to Vancomycin and Meropenem or Doripenem: A Retrospective Cohort Study].
Ide N; Sato S; Sawaguchi K
Yakugaku Zasshi; 2019; 139(12):1609-1614. PubMed ID: 31787651
[TBL] [Abstract][Full Text] [Related]
19. Comparison of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or cefepime.
Gomes DM; Smotherman C; Birch A; Dupree L; Della Vecchia BJ; Kraemer DF; Jankowski CA
Pharmacotherapy; 2014 Jul; 34(7):662-9. PubMed ID: 24753221
[TBL] [Abstract][Full Text] [Related]
20. The Risk of Acute Kidney Injury in Critically Ill Patients Receiving Concomitant Vancomycin With Piperacillin-Tazobactam or Cefepime.
Molina KC; Barletta JF; Hall ST; Yazdani C; Huang V
J Intensive Care Med; 2020 Dec; 35(12):1434-1438. PubMed ID: 30741072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
